Article Text
PDFTherapeutics
Randomised controlled trial
Intensive glucose lowering (HbA1c target<6.0%) for people with type 2 diabetes increases mortality
Statistics from Altmetric.com
Footnotes
-
Competing interests J Shaw has received lecturing fees, travel support and consultancy fees from Merck, Novartis, Pfizer, Novo Nordisk, Eli Lilly, Sanofi Aventis, Boehringer Ingelheim, Astra Zeneca, Bristol Myer Squibb.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions